2014 Conference on Retroviruses and Opportunistic Infections*

March 3-6, 2014; Boston, Massachusetts
Review Capsule Summaries, a slideset, and a module containing expert faculty analysis on the most clinically relevant studies from Boston.

HIV/AIDS Update From Boston 2014

Capsules

Vitamin D plus calcium supplementation was associated with a 50% reduction in hip BMD loss 48 weeks after initiation of efavirenz/emtricitabine/tenofovir DF in treatment-naive patients.

Released: March 8, 2014

Interim analysis finds no cases of linked HIV transmissions despite high levels of condomless sex.

Released: March 8, 2014

Interferon-free, all-oral regimen was shown to be effective and well tolerated in HIV/HCV-coinfected patients receiving ART.

Released: March 7, 2014

Coadministration of GS-9669 or GS-9451 with sofosbuvir/ledipasvir was well tolerated and allowed the therapy duration to be shortened from 12 weeks to 6 weeks while maintaining virologic efficacy.

Released: March 10, 2014

Interferon/RBV-free regimen comprising 3 direct-acting antiviral agents plus RTV was well tolerated and highly effective in a phase III trial conducted in therapy-naive noncirrhotic patients with genotype 1b HCV monoinfection.

Released: March 5, 2014

Effects of statin use on CD4+ cell recovery were observed across CD4+ cell count categories and were greatest after previous virologic failure.

Released: March 9, 2014

In this longitudinal study, the incidence of new-onset depression was significantly higher among antiretroviral-treated patients with persistent HIV-1 RNA detected in CSF

Released: March 7, 2014

Protective effect of GSK744 LA observed despite low vaginal:plasma concentration ratio.

Released: March 5, 2014

Lower rate of discontinuations due to adverse events with DTG-based regimen and no INST or NRTI resistance in patients with virologic failure of this regimen.

Released: March 11, 2014

Switching to the single-tablet regimen was associated with a higher rate of virologic suppression at Week 48 and was well tolerated.

Released: March 10, 2014

Switching to the single-tablet INSTI regimen was associated with consistently higher rates of virologic suppression and adverse events similar to those reported in earlier clinical studies when compared with regimens consisting of an NNRTI plus FTC/TDF.

Released: March 11, 2014

In ART-treated patients, time-updated viremia copy-years better predicts mortality vs most recent HIV-1 RNA level

Released: March 6, 2014

From 2000-2013, the frequency of resistance associated mutations in HIV-1 integrase remained low in treatment-naive patients recruited to clinical trials.

Released: March 9, 2014

Women treated with efavirenz in pregnancy experienced greater likelihood of virologic suppression than women treated with lopinavir/ritonavir, although both regimens were highly effective in preventing HIV transmission.

Released: March 7, 2014

Early ART initiation and virologic suppression was associated with depletion of the proviral reservoir in a cohort of perinatally HIV-infected youths.

Released: March 7, 2014

The reduced risk of MI in the HIV-infected population in recent years may be due to factors such as improvements in antiretroviral drug lipid effects, improvements in cardiovascular risk factors, and reductions in immunodeficiency.

Released: March 7, 2014

The association between abacavir use and risk of MI remained evident through continued follow-up despite decreasing prescription of abacavir to patients with elevated CVD risk.

Released: March 10, 2014

Normalization of CD4/CD8 ratio infrequent in patients initiating ART, but more common in younger patients, at higher CD4+ cell count, and with more recent ART initiation.

Released: March 9, 2014

Baseline markers of inflammation, immune activation independently associated with greater bone loss.

Released: March 7, 2014

Secondary analysis of the VOICE study finds significant association between method of injectable contraception and HIV acquisition risk.

Released: March 10, 2014

Safety profile was comparable between the 2 regimens, but resistance at failure was more common with the raltegravir-based regimen

Released: March 7, 2014

All regimens similar in time to virologic failure, but RAL superior to both PIs and DRV/RTV superior to ATV/RTV in composite efficacy and tolerability endpoint.

Released: March 8, 2014

Sensitive screening finds transmission frequency of key resistance mutations is 70% higher than previously estimated by conventional genotyping.

Released: March 8, 2014

Treatment-naive patients experienced fewer adverse events and had comparable virologic suppression rates to efavirenz-based regimens with regimens containing investigational oral integrase inhibitor over a 48-week study period.

Released: March 8, 2014
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?